Date: March 24, 2021
Time: 08:00am PDT
The liver is responsible for many metabolic, endocrine and exocrine functions. Approximately 2 million deaths per year are associated with liver failure. Modern 3D bioprinting technologies allied with autologous induced pluripotent stem cells (iPS)-derived grafts could represent a relevant tissue engineering approach to treat end stage liver disease patients. In this presentation, we will show how to differentiate human iPS towards relevant liver cellular phenotypes (hepatocytes, endothelial cells and mesenchymal cells) for 3D bioprinting. Also, we will evaluate the impacts of using single cell dispersion (i.e. obtained from conventional bidimensional differentiation) of iPS-derived parenchymal (i.e. hepatocyte-like cells) versus using iPS-derived hepatocyte-like cells spheroids (i.e. three-dimensional cell culture), both in combination with non-parenchymal cells, into final liver tissue functionality. These results will contribute to improve current liver bioprinting technology towards future regenerative medicine applications and liver physiology and disease modeling.
- Discuss iPS cell culture and quality control
- Describe differentiation and functional analysis of relevant liver cells phenotype (ie. hepatocytes, endothelial and MSC)
- Discuss 3D bioprinting human iPS-derived liver grafts in combination of 3D cultured hepatocyte-like cells
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.